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Background: Longitudinal associations between leukocyte subtype counts and LDL cholesterol have not
been reported.
Methods and Results: This is a retrospective observational study in a health screening population.
Spearman’s correlation coefﬁcients were calculated between leukocyte subtype counts and LDL
cholesterol levels at baseline and after four years. Using Cox regression models, hazard ratios (HRs) of
hyper-LDL cholesterolemia for leukocyte subtype counts during four years of follow-up were calculated
adjusted for age, sex, high-sensitivity C-reactive protein (hs-CRP) and other confounders. Spearman’s
correlation coefﬁcients (p values) between changes in counts of neutrophil, lymphocyte, monocyte,
basophil and eosinophil and changes in LDL cholesterol levels through 4 years were 0.02 (0.494), 0.12
(<0.001), 0.06 (0.016), 0.02 (0.524) and 0.03 (0.257), respectively among 1735 subjects who visited our
medical check-up center, did not use anti-hyperlipidemic drugs and revisited after 4 years. Among 1992
followed subjects, 481 developed hyper-LDL cholesterolemia during four years (60.4 per 1000 person-
years). The HRs (95% conﬁdence intervals; p values) of hyper-LDL cholesterolemia for each one SD in-
crease in counts of neutrophil, lymphocyte, monocyte, basophil and eosinophil were 1.08 (0.99e1.19;
0.085), 1.14 (1.04e1.25; 0.005), 1.05 (0.95e1.15; 0.339), 1.01 (0.92e1.11; 0.858) and 1.04 (0.95e1.14;
0.397), respectively.
Conclusions: Lymphocyte count and LDL cholesterol were longitudinally positively correlated and
lymphocyte count was associated with incidence of hyper-LDL cholesterolemia independently of hs-CRP
in a health screening population.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
While low-density lipoprotein (LDL) cholesterol remains the
most important risk factor for atherosclerosis, immune and in-
ﬂammatorymechanismsof atherosclerosis havegained tremendous
interest in the past 20 years [1,2]. In 1979, the adherence of mono-
cytes to the endothelium and the presence of monocytes within the
intima of hypercholesterolemic swine arteries were reported [3].
Although, initially, investigators thought that only macrophages are
predominantly present within atherosclerotic vessels, several
studies reported the presence of most known leukocyte subtypes
such as T and B lymphocytes, natural killer cells (NK) and NKT cells,natural killer; hs-CRP, high-
HR, hazard ratio; HDL, high-
BY-NC-ND license (http://
þ81 258 34 1113.
Published by Elsevier Inc. All righmacrophages, dendritic cells and mast cells within atherosclerosis-
prone arteries [2,4]. Thus, atherosclerosis is thought to be a
chronic inﬂammatory disease and an increasing body of evidence
suggests that the immune system actively participates in the initi-
ation, progression and persistence of atherosclerosis [5]. The pres-
ence of inﬂammatory cells in atherosclerotic lesions depends on the
rate of their recruitment and egress and the balance of proliferation,
survival, andapoptosiswithin thearterialwall. Total leukocyte count
in peripheral blood is associatedwith coronary heart disease among
patients with diabetes [6] and an independent predictor of cardio-
vascular disease and all-cause mortality in postmenopausal women
[7]. A pro-inﬂammatory role for neutrophils is also suggested in the
development of atherosclerosis [8]. Leukocyte subtype counts in
peripheral blood may be associated with complex dynamic pro-
cesses in atherosclerotic lesions. The previous literature on leuko-
cyte counts has largely focused on total leukocyte and neutrophil
counts, and smoking is a key determinant of total leukocyte and
neutrophil counts. However, studies on the associations between
leukocyte subtype counts and cardiovascular disease or its riskts reserved.
Table 1
Laboratory data of the subjects in the correlation study
n At baseline After 4 years pa
n (male %) 1735 (66.1) 1735 (66.1)
Age (years) 50.7 (9.0) 54.8 (9.0)
Body mass index (kg/m2) 22.6 (3.0) 22.7 (3.1) 0.169
Systolic blood pressure (mm Hg) 118.2 (17.5) 118.2 (15.1) 0.988
Diastolic blood pressure (mm Hg) 74.8 (10.9) 78.0 (11.4) <0.001
Neutrophil count (/L6) 2999 (1056) 2915 (1197) 0.028
Lymphocyte count (/L6) 1808 (515) 1711 (491) <0.001
Monocyte count (/L6) 277 (94) 270 (95) 0.032
Eosinophil count (/L6) 169 (135) 165 (132) 0.330
Basophil count (/L6) 31 (22) 32 (21) 0.020
High-sensitivity CRP (mg/L) 0.62 (1,79) 0.75 (2.47) 0.074
LDL cholesterol (mmol/L) 3.07 (0.72) 3.09 (0.73) 0.521
HDL cholesterol (mmol/L) 1.60 (0.39) 1.54 (0.39) <0.001
Triglycerides (mmol/L) 1.18 (0.72) 1.19 (0.78) 0.717
Fasting glucose (mmol/L) 5.15 (0.68) 5.23 (0.81) 0.001
Aspartate aminotransferase (U/L) 23.1 (19.9) 22.9 (9.5) 0.706
Alanine aminotransferase (U/L) 23.6 (18.8) 23.2 (16.5) 0.490
Mean (SD) except for n (male%).
a paired t-tests.
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report regarding a longitudinal association between leukocyte
subtype counts and LDL cholesterol. In the present retrospective
observational study, longitudinal associations between leukocyte
subtype counts and LDL cholesterol were investigated in a health
screening Japanese population. The protocol for this study was
approved by the ethics committee of Tachikawa Medical Center.
Subjects and methods
Subjects
Between April 2008 and March 2009, 3866 subjects visited our
medical check-up center for annual health screening and gave
signed informed consent. The visitors were required to ﬁll out a
questionnaire including questions about their history of ischemic
heart disease and stroke, smoking and drinking status, level of
physical activity and use of antihypertensive, antidiabetic and
antihyperlipidemic drugs. Among them, 1735 subjects did not use
antihyperlipidemic drugs and revisited our medical check-up cen-
ter between April 2012 and March 2013, and were included in the
longitudinal correlation study. Subtracting 1278 subjects with
hyper-LDL cholesterolemia from the 3866 subjects, 2588 subjects
became potential candidates for the follow-up study. Among them,
1992 subjects revisited our medical check-up center between April
2009 and March 2013 and were actually followed. Hyper-LDL
cholesterolemia was deﬁned as LDL cholesterol 140 mg/dL ac-
cording to the Guidelines by Japan Atherosclerosis Society [20] and/
or use of antihyperlipidemic drugs.
Measurements
After an overnight fast, blood samples were obtained to measure
blood levels of routine medical check-up parameters including LDL
cholesterol, high-sensitivity C-reactive protein (hs-CRP) and leuko-
cyte subtypecounts.ChemicalmeasurementswereperformedatBML
Nagaoka (Nagaoka, Japan)with routine laboratorymethodsexcept for
hs-CRP which was measured at BML General Laboratory (Tokyo,
Japan) with nephelometry using N-latex CRP-2 (Siemens Healthcare
Japan, Tokyo, Japan). Themeasurement limit of hs-CRPwas 0.02mg/L
and the level of hs-CRP less than the measurement limit was
considered as 0.01 mg/L. LDL cholesterol was measured with a direct
surfactant method using Choletest-LDL (Sekisui Medical Inc., Tokyo,
Japan). Leukocyte subtype counts were measured with ﬂow cytom-
etry using XE-2100 (Sysmex Inc., Kobe, Japan) where the subtypes
were determined based on FSC/SSC. Average systolic and diastolic
blood pressures were calculated from twomeasurements in a sitting
position after each 5 min rest. Body weight was measured with the
subjects wearing light clothes provided by our center and theweight
of the clothingwas subtracted from themeasured bodyweight. Body
mass index (BMI)wascalculatedasweight inkilogramsdividedby the
square of height in meters.
Statistical analysis
Correlation study
Laboratory data at baseline and after 4 years were compared by
paired t-tests. Spearman’s correlation coefﬁcients between leuko-
cyte subtype counts at baseline and after 4 years and their changes
through 4 years and LDL cholesterol levels at baseline and after 4
years and their changes through 4 years were calculated.
Follow-up study
Baseline data were compared between potential candidates and
actually followed subjects. Baseline data of the actually followedsubjects were also compared between subjects who developed
hyper-LDL cholesterolemia and those who did not.
Using Cox regression models in which years were used as a unit
of the survival variable and drop-out subjects were considered,
hazard ratios (HRs) of hyper-LDL cholesterolemia for one SD in-
crease in counts of neutrophil, lymphocyte, monocyte, basophil and
eosinophil were calculated adjusted for hs-CRP, sex, age, current
smoking, daily drinking, physical activity, history of ischemic heart
disease and stroke, and use of antihypertensive and antidiabetic
drugs (Model 1), and farther adjusted for LDL cholesterol per se
(Model 2). Physical activity was deﬁned as walking for 1 h or longer
per day or exercising for 30 min or longer twice or more per week.
The HR calculations were repeated separately in 497 smokers
and 1495 nonsmokers and after the redeﬁnition of hyper-LDL
choesterolemia as LDL cholesterol 160 mg/dL and/or use of anti-
hyperlipidemic drugs.
Incidence of hyper-LDL cholesterolemia expressed per 1000
person-years and hazard ratio (HR) of hyper-LDL cholesterolemia
adjusted for Model 1 were calculated for each quartile of lympho-
cyte count. The lowest quartile of lymphocyte count was used as
reference group for the calculation of HRs.
Statistical analyses were performed using Dr-SPSS-2 (IBM Japan,
Tokyo, Japan). Means were compared with paired or unpaired two-
sided t-tests and percentages were compared with chi-squared
tests. Except for correlation coefﬁcients, p values of lower than
0.05 were considered statistically signiﬁcant. For correlation co-
efﬁcients, p values of lower than 0.001 were considered statistically
signiﬁcant.
Results
Correlation study
Laboratory data at baseline and after 4 years of the subjects in
the correlation study are presented in Table 1. The neutrophil,
lymphocyte and monocyte counts and HDL cholesterol were
signiﬁcantly lower and basophil count, diastolic blood pressure, and
fasting glucose were signiﬁcantly higher after 4 years than at
baseline. Spearman’s correlation coefﬁcients between leukocyte
subtype counts and LDL cholesterol are shown in Table 2. Among
the 5 leukocyte subtype counts at baseline, only lymphocyte count
was signiﬁcantly positively correlated with LDL cholesterol both at
baseline and after 4 years. Among the 5 leukocyte subtype counts
after 4 years, only lymphocyte count was signiﬁcantly positively
Table 2
Spearman’s correlation coefﬁcients (p values) between LDL cholesterol and leukocyte subtype counts
Neutrophil Lymphocyte Monocyte Eosinophil
Between leukocyte subtype counts at baseline
LDL cholesterol at baseline 0.04 (0.117) 0.16 (<0.001) 0.02 (0.457) 0.04 (0.120)
LDL cholesterol after 4 years 0.03 (0.230) 0.09 (<0.001) 0.03 (0.197) 0.01 (0.723)
Changes in LDL cholesterol 0.02 (0.532) 0.10 (<0.001) 0.07 (0.007) 0.04 (0.062)
Between leukocyte subtype counts after 4 years
LDL cholesterol at baseline 0.06 (0.019) 0.13 (<0.001) 0.01 (0.625) 0.05 (0.032)
LDL cholesterol after 4 years 0.04 (0.064) 0.11 (<0.001) 0.04 (0.123) 0.03 (0.154)
Changes in LDL cholesterol 0.01 (0.549) 0.02 (0.358) 0.02 (0.367) 0.02 (0.360)
Between changes in leukocyte subtype counts
LDL cholesterol at baseline 0.01 (0.825) 0.06 (0.007) 0.04 (0.133) 0.02 (0.317)
LDL cholesterol after 4 years 0.00 (0.995) 0.02 (0.337) 0.01 (0.795) 0.04 (0.121)
Changes in LDL cholesterol 0.02 (0.494) 0.12 (<0.001) 0.06 (0.016) 0.02 (0.524)
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leukocyte subtype counts, only changes in lymphocyte count was
signiﬁcantly positively correlated with the changes in LDL choles-
terol. Any basophil count was not signiﬁcantly associated with any
LDL cholesterol.
Follow-up study
Therewere no signiﬁcant differences in the baseline data between
the candidates and followed subjects. Among the 1992 followed
subjects, 481 (60.4 per 1000 person-years) developed hyper-LDL
cholesterolemia during 4 years (mean of 3.1 years). Baseline data
stratiﬁedaccording to thedevelopmentof hyper-LDL cholesterolemia
are shown in Table 3. The means of age, BMI, lymphocyte count, LDL
cholesterol, triglycerides and alanine aminotransferase were signiﬁ-
cantlyhigherwhile themeanofHDLcholesterol and theprevalenceof
daily drinking were signiﬁcantly lower in subjects who developed
hyper-LDL cholesterolemia than those who did not.
Hazard ratios of hyper-LDL cholesterolemia for each one SD in-
crease in leukocyte subtype counts are presented in Table 4. Among
the 5 leukocyte subtype counts, only lymphocyte count was signif-
icantly associated with the incidence of hyper-LDL cholesterolemiaTable 3
Baseline data stratiﬁed according to the development of hyper-LDL cholesterolemia
Developers Non-developers p
n 481 1511
Male % 62.2 66.1 0.113
Age (years) 52.1 (8.7) 50.7 (9.6) 0.007
Body mass index (kg/m2) 22.8 (3.0) 22.1 (2.9) <0.001
Systolic blood pressure (mm Hg) 118.9 (18.1) 117.6 (17.7) 0.149
Diastolic blood pressure (mm Hg) 74.9 (11.6) 74.3 (11.1) 0.321
Neutrophil count (/L6) 3047 (1126) 2962 (1081) 0.137
Lymphocyte count (/L6) 1815 (547) 1757 (490) 0.030
Monocyte count (/L6) 278 (97) 277 (94) 0.821
Eosinophil count (/L6) 168 (132) 171 (140) 0.718
Basophil count (/L6) 30 (20) 30 (21) 0.840
High-sensitivity CRP (mg/L) 0.64 (1.17) 0.56 (1.47) 0.238
LDL cholesterol (mmol/L) 3.20 (0.32) 2.70 (0.52) <0.001
HDL cholesterol (mmol/L) 1.54 (0.37) 1.65 (0.42) <0.001
Triglycerides (mmol/L) 1.33 (0.94) 1.08 (0.70) <0.001
Fasting glucose (mmol/L) 5.21 (0.84) 5.14 (0.69) 0.076
Aspartate aminotransferase (U/L) 22.9 (11.2) 22.7 (20.9) 0.822
Alanine aminotransferase (U/L) 23.8 (19.6) 21.9 (16.7) 0.043
Antihypertensive drugs 15.6 13.7 0.300
Antidiabetic drugs 2.1 1.8 0.679
History of stroke 0.8 1.3 0.446
History of ischemic heart disease 2.3 2.1 0.824
Current smoking 22.5 25.7 0.146
Daily alcohol drinking 34.9 44.3 <0.001
Physical activitya 34.3 37.9 0.160
Mean (SD) or %.
a Deﬁned as walking for 1 h or longer per day or exercising for 30 min or longer
twice or more per week.in Model 1 while no leukocyte subtype count was signiﬁcantly
associated with the incidence of hyper-LDL cholesterolemia in
Model 2 in all subjects and non-smokers. No leukocyte subtype
count was signiﬁcantly associated with the incidence of hyper-LDL
cholesterolemia in smokers.
When hyper-LDL cholesterolemia was redeﬁned as LDL choles-
terol 160 mg/dL and/or use of antihyperlipidemic drugs, among
3492 candidate subjects at baseline, 2423 subjects (607 smokers
and 1816 nonsmokers) revisited between April 2012 and March
2013, and 233 subjects (58 smokers and 175 nonsmokers) devel-
oped hyper-LDL cholesterolemia during 4 years. HRs of the rede-
ﬁned hyper-LDL cholesterolemia for each one SD increase in
leukocyte subtype counts are presented in Table 5. No leukocyte
subtype count was signiﬁcantly associated with the incidence of
hyper-LDL cholesterolemia. However, lymphocyte count was
marginally associated with the incidence of hyper-LDL cholester-
olemia in Model 1 in all subjects and non-smokers.
Incidence and hazard ratio (HR) of hyper-LDL cholesterolemia
for each quartile of lymphocyte count are shown in Table 6. There
were signiﬁcant associations between the quartile of lymphocyte
count and the incidence (p for trend ¼ 0.036) as well as the hazard
ratio (p for trend ¼ 0.005) of hyper-LDL cholesterolemia.Table 4
Hazard ratios of hyper-LDL cholesterolemia for each one SD increase in leukocyte
subtype counts
Model 1a Model 2b
Hazard ratio
(95% CIc)
p Hazard ratio
(95% CIc)
p
All subjects
Neutrophil count 1.08 (0.99e1.19) 0.085 1.04 (0.95e1.14) 0.405
Lymphocyte count 1.14 (1.04e1.25) 0.005 1.03 (0.93e1.13) 0.569
Monocyte count 1.05 (0.95e1.15) 0.339 1.00 (0.91e1.10) 0.999
Eosinophil count 1.01 (0.92e1.11) 0.858 0.96 (0.88e1.06) 0.415
Basophil count 1.04 (0.95e1.14) 0.397 0.99 (0.91e1.09) 0.870
Smokers
Neutrophil count 1.14 (0.98e1.31) 0.088 1.06 (0.91e1.23) 0.469
Lymphocyte count 1.10 (0.93e1.30) 0.280 1.04 (0.86e1.26) 0.663
Monocyte count 1.00 (0.84e1.19) 0.998 0.92 (0.77e1.10) 0.354
Eosinophil count 0.92 (0.76e1.11) 0.401 0.91 (0.75e1.11) 0.354
Basophil count 1.06 (0.89e1.27) 0.514 1.03 (0.85e1.24) 0.776
Non-smokers
Neutrophil count 1.05 (0.94e1.18) 0.359 1.04 (0.93e1.16) 0.519
Lymphocyte count 1.15 (1.03e1.27) 0.013 1.02 (0.91e1.14) 0.749
Monocyte count 1.05 (0.94e1.18) 0.359 1.04 (0.93e1.17) 0.498
Eosinophil count 1.04 (0.94e1.16) 0.439 0.97 (0.87e1.08) 0.535
Basophil count 1.04 (0.93e1.15) 0.498 0.98 (0.88e1.09) 0.696
a Adjusted for high-sensitivity CRP, sex, age, current smoking, daily drinking,
physical activity, histories of ischemic heart disease and stroke, and uses of anti-
hypertensive and antidiabetic drugs.
b Adjusted for covariates in Model 1 plus LDL cholesterol.
c Conﬁdence interval.
Table 5
Hazard ratios of hyper-LDL cholesterolemia deﬁned as 160 mg/dL for each one SD
increase in leukocyte subtype counts
Model 1a Model 2b
Hazard ratio
(95% CIc)
p Hazard ratio
(95% CIc)
p
All subjects
Neutrophil count 0.99 (0.87e1.13) 0.870 0.91 (0.79e1.04) 0.168
Lymphocyte count 1.13 (1.00e1.28) 0.054 0.98 (0.85e1.11) 0.708
Monocyte count 1.05 (0.92e1.19) 0.457 0.98 (0.85e1.12) 0.726
Eosinophil count 1.02 (0.90e1.15) 0.751 1.00 (0.88e1.14) 0.976
Basophil count 1.03 (0.91e1.16) 0.690 0.96 (0.85e1.09) 0.527
Smokers
Neutrophil count 1.09 (0.90e1.33) 0.381 0.97 (0.79e1.19) 0.748
Lymphocyte count 1.10 (0.89e1.37) 0.377 0.92 (0.72e1.17) 0.497
Monocyte count 1.11 (0.90e1.37) 0.328 0.94 (0.74e1.19) 0.613
Eosinophil count 1.03 (0.83e1.28) 0.760 0.96 (0.75e1.23) 0.744
Basophil count 1.06 (0.86e1.30) 0.612 0.94 (0.75e1.18) 0.595
Nonsmokers
Neutrophil count 0.92 (0.77e1.09) 0.347 0.86 (0.71e1.03) 0.095
Lymphocyte count 1.15 (0.99e1.33) 0.073 0.99 (0.84e1.16) 0.892
Monocyte count 1.02 (0.87e1.20) 0.816 0.99 (0.84e1.17) 0.900
Eosinophil count 1.01 (0.87e1.18) 0.890 1.02 (0.87e1.18) 0.846
Basophil count 1.01 (0.87e1.18) 0.868 0.97 (0.83e1.13) 0.708
a Adjusted for high-sensitivity CRP, sex, age, current smoking, daily drinking,
physical activity, histories of ischemic heart disease and stroke, and uses of anti-
hypertensive and antidiabetic drugs.
b Adjusted for covariates in Model 1 plus LDL cholesterol.
c Conﬁdence interval.
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In the present longitudinal study, the baseline lymphocyte count
was signiﬁcantly positively correlated with the LDL cholesterol
levels after 4 years, the changes in lymphocyte count were signif-
icantly correlated with the changes in LDL cholesterol and the
baseline lymphocyte count was associated with the incidence of
hyper-LDL cholesterolemia adjusted for hs-CRP, a marker of non-
speciﬁc inﬂammation, in a health screening population. However,
lymphocyte count was not signiﬁcantly associated with the inci-
dence of hyper-LDL cholesterolemia after further adjusted for LDL
cholesterol itself, and it was not signiﬁcantly associated with the
incidence of hyper-LDL cholesterolemia in smokers. Therefore,
leukocyte count may not be a clinically useful predictor of hyper-
LDL cholesterolemia and an increase in neutrophil count in
smokers might confound the association between lymphocyte
count and hyper-LDL cholesterolemia.
Total leukocyte count was associated with obesity, hyper-
tension, hypercholesterolemia, hypo-HDL cholesterolemia, hyper-
triglyceridemia, hyperglycemia, hyperuricemia and metabolic
syndrome (MetS) [21e23]. Total leukocyte count and hs-CRP
equally predicted development of MetS, but both are poorTable 6
Incidence and hazard ratio of hyper-LDL cholesterolemia for each quartile of
lymphocyte count
Q1 Q2 Q3 Q4 p for
trend
Lymphocyte
count
469e1428 1429e1711 1712e2050 2051e4144
n 499 498 498 497
Incidencea 61.5 49.8 55.8 74.5 0.036
Hazard ratiob 1.00 0.84 0.95 1.39 0.005
95% Conﬁdence
interval
0.64e1.09 0.73e1.25 1.08e1.81
p 0.192 0.732 0.012
a Per 1000 person-years.
b Compared with Q1 adjusted for high-sensitivity CRP, sex, age, current smoking,
daily drinking, physical activity, histories of ischemic heart disease and stroke, and
uses of antihypertensive and antidiabetic drugs.predictors of MetS in a health screening Japanese population [24],
although hs-CRP is superior to total leukocyte count as an inﬂam-
matory component of MetS in a cross-sectional study [25]. Total
leukocyte count is also reported to be a predictor of coronary heart
disease [6], even after adjusted for hs-CRP [7].
Cross-sectional associations between leukocyte subtype counts
and cardiovascular risk factors are controversial [9e14]. Oda et al.
previously reported that the lymphocyte count was signiﬁcantly
associated with hyper-LDL cholesterolemia, hypertriglyceridemia,
and hypo-HDL cholesterolemia in men and hyper-LDL cholester-
olemia in women [15].
Regarding longitudinal associations between leukocyte subtype
countsanddiseaseprogression inhigh-riskpopulations,Nozawaet al.
reported that monocyte count, but not lymphocyte or neutrophil
count, was associated with coronary plaque progression after acute
myocardial infarction [16]. Giugliano et al. reported that neutrophil
count, but not lymphocyte or monocyte count, was associated with
increased cardiovascular risk in patients with peripheral artery dis-
ease [17]. Papa et al. showed that neutrophil to lymphocyte ratio was
an independent predictor of cardiac mortality in patients with stable
angina [18]. ó Hartaigh et al. reported that neutrophil count and
neutrophil to lymphocyte ratio was independent predictors of car-
diovascular mortality in a high-risk population [19].
The present study demonstrated that the lymphocyte, not
neutrophil or monocyte, count was associated with the incidence of
hyper-LDL cholesterolemia in a health screening population after
adjusted for hs-CRP, amarker of non-speciﬁc inﬂammation, and that
the changes in lymphocyte count were signiﬁcantly correlated with
the changes in LDL cholesterol. Although exact mechanisms under-
lying the association between baseline lymphocyte count and
incidence of hyper-LDL cholesterolemia are unknown, the cross-
sectional positive correlation between lymphocyte count and LDL
cholesterol levels might play an important role because this asso-
ciation between baseline lymphocyte count and incidence of hyper-
LDL cholesterolemia became non-signiﬁcant after further adjusted
for LDL cholesterol levels at baseline. Atherosclerosis starts with an
innate immune response involving the recruitment and activation of
monocytes that respond to an excessive accumulation of modiﬁed
lipids within the arterial wall, followed by an adaptive immune
response involving antigen-speciﬁc T lymphocytes [8]. Thus, the
following scenario can be speculated. Increased LDL cholesterol
levels result in an excessive accumulation of modiﬁed lipids within
the arterial wall and subsequent recruitment and activation of
monocytes, followed by the recruitment of lymphocytes which
respond antigen-presenting activated macrophages, and this
recruitment and activation of lymphocytes may stimulates the
proliferation and mobilization of lymphocytes from lymphoid tis-
sues, resulting in an increased lymphocyte count inperipheral blood.
In contrast to the above reports that monocyte and/or neutrophil
counts, not lymphocyte count, were associated with disease pro-
gression in high-risk populations with advanced atherosclerotic
diseases, the present results suggest that adaptive immune mecha-
nisms mediated by lymphocytes may importantly participate in
early stages of atherosclerotic lesion formation in accordwithhyper-
LDL cholesterolemia beyond innate immunemechanisms mediated
by monocytes and neutrophils.
Limitations
The present study was a retrospective observational study and
the subjects were not recruited from a general population but
recruited from a general health screening population. The number
of subjects might be inadequate to ﬁnd a signiﬁcant association
between lymphocyte count and hyper-LDL cholesterolemia when it
was deﬁned as LDL cholesterol 160 mg/dL and/or use of
E. Oda / Journal of Clinical & Translational Endocrinology 1 (2014) 49e53 53antihyperlipidemic drugs. Detailed information about demographic
backgrounds and dietary habits was not available and lymphocyte
subtypes were not measured in this study.
Conclusions
The present study demonstrated that lymphocyte, not neutro-
phil or monocyte, count, was signiﬁcantly associated with inci-
dence of hyper-LDL cholesterolemia adjusted for hs-CRP, a marker
of non-speciﬁc inﬂammation, and lymphocyte count and LDL
cholesterol were longitudinally positively correlated with each
other. The present results suggest that the adaptive immune system
mediated by lymphocytes may importantly participate in early
stages of atherosclerotic lesion formation associated with hyper-
LDL cholesterolemia beyond innate immune mechanisms medi-
ated by monocytes and neutrophils.
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